---
id: acr-spond-2024
title: "2024 ACR/SPARTAN Recommendations for the Treatment of Axial Spondyloarthritis"
short_title: "Axial Spondyloarthritis"
organization: American College of Rheumatology / SPARTAN
country: United States
url: https://onlinelibrary.wiley.com/doi/10.1002/art.42711
specialty: rheumatology
guideline_type: clinical-practice
evidence_system: acr-grade
conditions:
  - Ankylosing Spondylitis
  - Axial Spondyloarthritis
  - Non-Radiographic Axial SpA
tags:
  - spondyloarthritis
  - ankylosing spondylitis
  - biologics
  - TNF inhibitor
publication_date: 2024-04-01
previous_version_date: 2019-02-01
status: current
supersedes: acr-as-2019
superseded_by: null
pdf_path: null
has_pdf: false
last_reviewed: 2025-01-01
---

## Scope

This guideline provides updated recommendations for the treatment of axial spondyloarthritis (axSpA), including ankylosing spondylitis (radiographic axSpA) and non-radiographic axSpA.

## Key Recommendations

### First-Line Therapy
**NSAIDs:**
- Continuous or on-demand NSAID therapy
- Trial of â‰¥2 NSAIDs before escalation
- Continuous preferred for sustained inflammation

### Biologic DMARDs
**TNF Inhibitors (First-Line Biologic):**
- Adalimumab, etanercept, certolizumab, golimumab, infliximab
- Consider for NSAID inadequate response
- No preference among TNF inhibitors

**IL-17 Inhibitors:**
- Secukinumab, ixekizumab
- Alternative first-line biologic or after TNF inadequate response
- Preferred if concomitant psoriasis

### JAK Inhibitors
- Tofacitinib, upadacitinib
- Option after biologic inadequate response
- Consider cardiovascular/thrombosis risk

### Treat-to-Target
- Aim for remission or low disease activity
- ASDAS as preferred measure
- Regular assessment of disease activity

### Physical Therapy
- Regular exercise program (essential adjunct)
- Physical therapy referral
- Maintain spinal mobility

### Not Recommended
- Methotrexate, sulfasalazine for axial disease
- Systemic glucocorticoids
- Local glucocorticoid injections for SI joints: Conditional use

### Peripheral Manifestations
- Sulfasalazine or methotrexate may help peripheral arthritis
- TNFi or IL-17i if biologic needed

### Extra-Articular Manifestations
- Uveitis: TNF monoclonal antibodies preferred over etanercept
- IBD: TNF monoclonal antibodies (not etanercept or IL-17i)
